DNMT1 and ovarian carcinoma: The combination of EZH2 and DNMT1 inhibitors in ovarian cancer also promoted the intratumoral expression of TH1 chemokines (CXCL9 and CXCL10) expression, which correlated with improved efficacy of adoptive T cell transfer and checkpoint inhibition (220).